Boehringer’s Olodaterol Gains Advisory Committee Support, But May See Indication Clarified
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee voted 15-1 that efficacy and safety had been shown, but said the label should not imply it is a treatment for chronic bronchitis and emphysema, just airway obstruction in those conditions, as well as COPD.
You may also be interested in...
Boehringer’s Striverdi Respimat Approved For COPD, But Without Exercise Claim
The long-acting beta agonist olodaterol cleared FDA for treatment of chronic obstructive pulmonary disease, but it didn’t gain the differentiating claim the German pharma was seeking.
Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues
FDA Pulmonary-Allergy Drugs Advisory Committee to review NDA for COPD and will discuss safety results from trial comparing inhalation spray to powder.
BI’s Olodaterol Wants Novel Exercise Claims In COPD
Proposed claims for Striverdi Respimat include improved exercise tolerance and increased inspiratory capacity, but FDA has no clear regulatory pathway for them.